Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT): Price and Financial Metrics


Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT)

Today's Latest Price: $5.84 USD

0.02 (0.34%)

Updated Dec 2 4:00pm

Add OSMT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

OSMT Stock Summary

  • Osmotica Pharmaceuticals plc's stock had its IPO on October 18, 2018, making it an older stock than merely 4.92% of US equities in our set.
  • With a year-over-year growth in debt of -18.71%, Osmotica Pharmaceuticals plc's debt growth rate surpasses only 15.68% of about US stocks.
  • Revenue growth over the past 12 months for Osmotica Pharmaceuticals plc comes in at -17.31%, a number that bests just 20.58% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Osmotica Pharmaceuticals plc are ORBC, LIVN, OPK, SANW, and SCOR.
  • OSMT's SEC filings can be seen here. And to visit Osmotica Pharmaceuticals plc's official web site, go to www.osmotica.com.

OSMT Stock Price Chart Interactive Chart >

Price chart for OSMT

OSMT Price/Volume Stats

Current price $5.84 52-week high $9.67
Prev. close $5.82 52-week low $2.81
Day low $5.72 Volume 131,042
Day high $5.96 Avg. volume 383,750
50-day MA $5.77 Dividend yield N/A
200-day MA $5.36 Market Cap 300.88M

Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) Company Bio


Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women's health. The company was founded on July 13, 2017 and is headquartered in Bridgewater, NJ.

OSMT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$5.84$0.25 -96%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Osmotica Pharmaceuticals plc. To summarize, we found that Osmotica Pharmaceuticals plc ranked in the 6th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 96%. The most interesting components of our discounted cash flow analysis for Osmotica Pharmaceuticals plc ended up being:

  • The company's balance sheet shows it gets 63% of its capital from equity, and 37% of its capital from debt. Its equity weight surpasses that of only 16.84% of free cash flow generating stocks in the Healthcare sector.
  • The company's compound free cash flow growth rate over the past 2.11 years comes in at -0.31%; that's greater than merely 4.69% of US stocks we're applying DCF forecasting to.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-96%
1%-96%
2%-96%
3%-96%
4%-96%
5%-96%

NVST, LUMO, INFU, PHG, and PPD can be thought of as valuation peers to OSMT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


OSMT Latest News Stream


Event/Time News Detail
Loading, please wait...

OSMT Latest Social Stream


Loading social stream, please wait...

View Full OSMT Social Stream

Latest OSMT News From Around the Web

Below are the latest news stories about Osmotica Pharmaceuticals plc that investors may wish to consider to help them evaluate OSMT as an investment opportunity.

Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call Transcript

Start Time: 16:30 End Time: 17:30 Osmotica Pharmaceuticals plc (OSMT) Q2 2020 Earnings Conference Call August 11, 2020, 16:30 PM ET Company Participants Brian Markison - Chairman and CEO Andrew Einhorn - CFO James Schaub - EVP and COO Derek Cunningham - Director of Optometry and Research, Dell Laser Consultants...

SA Transcripts on Seeking Alpha | August 12, 2020

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

July turned out to be a mixed month for FDA approvals. Endo International PLC's (NASDAQ: ENDP ) cellulite treatment, Osmotica Pharmaceuticals PLC's (NASDAQ: OSMT ) eye disorder drug and Jazz Pharmaceuticals PLC's (NASDAQ: JAZZ ) drug to treat excessive daytime sleepiness were among those which successfully cleared the FDA hurdle. A few others, including Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) and Eagle Pharmaceuticals Inc (NASDAQ: EGRX ), are forced to wait. The regulatory agency handed down a complete response letter for Verrica's viral skin infection treatment, while Eagle Pharma's PDUFA date for its exertional heat stroke drug was postponed until Aug. 8 due to FDA's reallocation of resources due to COVID-19. Four new molecular entities, or NMEs, were approved in July, taking the ...

Benzinga | July 31, 2020

Osmotica out-licenses droopy eyelid med to Santen Pharma

Osmotica (OSMT) unit RVL Pharmaceuticals inks an agreement with Santen Pharmaceutical Co. granting the latter exclusive development and commercialization rights to RVL-1201 in Europe, the Middle East, Africa, Japan, China and other Asian countries for the treatment of acquired blepharoptosis (droopy eyelid) in adults.Under the terms of the deal, OSMT...

Seeking Alpha | July 28, 2020

Osmotica Pharmaceutical US LLC Announces FDA User Fee Goal Date of December 29, 2020 for Arbaclofen Extended Release Tablets

BRIDGEWATER, N.J., July 20, 2020 -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully.

Yahoo | July 20, 2020

Why Osmotica Pharmaceuticals Is Plunging Today

Shares of Osmotica Pharmaceuticals (NASDAQ: OSMT), a small-cap biopharmaceutical company, are down by 20.4% as of 11:26 a.m. EDT on Tuesday, following the company's announcement on Monday evening of the pricing of a public offering of common stock. Investors aren't thrilled with the prospect of Osmotica resorting to dilutive forms of financing. Osmotica said it would offer 5 million shares to the public for $6.55 per share.

Yahoo | July 14, 2020

Read More 'OSMT' Stories Here

OSMT Price Returns

1-mo 8.96%
3-mo 4.10%
6-mo -15.12%
1-year -14.37%
3-year N/A
5-year N/A
YTD -16.45%
2019 -9.81%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching OSMT

Want to see what other sources are saying about Osmotica Pharmaceuticals plc's financials and stock price? Try the links below:

Osmotica Pharmaceuticals plc (OSMT) Stock Price | Nasdaq
Osmotica Pharmaceuticals plc (OSMT) Stock Quote, History and News - Yahoo Finance
Osmotica Pharmaceuticals plc (OSMT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8994 seconds.